Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non Operating Income: 2023-2025

Historic Non Operating Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $2.7 million.

  • Monte Rosa Therapeutics' Non Operating Income fell 0.80% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 34.78%. This contributed to the annual value of $11.0 million for FY2024, which is 32.36% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Non Operating Income stood at $2.7 million, which was down 39.05% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Non Operating Income peaked at $4.5 million during Q2 2025, and registered a low of $1.6 million during Q4 2023.
  • For the 3-year period, Monte Rosa Therapeutics' Non Operating Income averaged around $2.7 million, with its median value being $2.6 million (2024).
  • Within the past 5 years, the most significant YoY rise in Monte Rosa Therapeutics' Non Operating Income was 72.52% (2025), while the steepest drop was 0.80% (2025).
  • Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Non Operating Income stood at $1.6 million in 2023, then spiked by 63.44% to $2.6 million in 2024, then fell by 0.80% to $2.7 million in 2025.
  • Its Non Operating Income was $2.7 million in Q3 2025, compared to $4.5 million in Q2 2025 and $3.7 million in Q1 2025.